InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders

July 27th, 2023

Milan, Lyon

InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a collaborative partnership with Axoltis Pharma, a biopharmaceutical company committed to developing disease-modifying drugs for patients with high unmet medical needs in neurodegenerative and traumatic neurologic impairments. This strategic collaboration works to revolutionize our understanding of Central Nervous System (CNS) diseases and to optimize the clinical development plan of Axoltis’ drug candidate, NX210c, a promising 12-amino acid peptide derived from SCO-spondin. Read More (PDF Press release)